North China Pharmaceutical Company.Ltd (SHA:600812)
China · Delayed Price · Currency is CNY 4.830
-0.130 (-2.62%)
May 20, 2026, 11:29 AM CST
SHA:600812 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 161.04 | 183.06 | 126.99 | 4.89 | -689.23 | 18.73 |
Depreciation & Amortization | 940.14 | 940.14 | 863.4 | 878.05 | 779.02 | 703.23 |
Other Amortization | 19.54 | 19.54 | 12.01 | 10.79 | 10.41 | 8.68 |
Loss (Gain) From Sale of Assets | -0.83 | -0.83 | -0.44 | -0.76 | -0.44 | -3.4 |
Asset Writedown & Restructuring Costs | 0.76 | 0.76 | 4.73 | 0.05 | 0.24 | - |
Loss (Gain) From Sale of Investments | -60.63 | -60.63 | -46.16 | -46.85 | -44.02 | -39.12 |
Provision & Write-off of Bad Debts | 44.29 | 44.29 | 41.5 | 10.56 | 44.94 | 22.77 |
Other Operating Activities | 435.23 | 417.86 | 539.63 | 550.93 | 1,404 | 641.66 |
Change in Accounts Receivable | -197.85 | -197.85 | 377.13 | 342.83 | -578.35 | -329.25 |
Change in Inventory | 118.9 | 118.9 | 94.32 | -87.11 | -191.92 | 86.61 |
Change in Accounts Payable | -283.44 | -283.44 | -792.32 | -637.27 | 275.22 | -58.2 |
Operating Cash Flow | 1,172 | 1,177 | 1,230 | 1,024 | 1,004 | 1,050 |
Operating Cash Flow Growth | 41.91% | -4.31% | 20.04% | 1.98% | -4.37% | 39.63% |
Capital Expenditures | -544.22 | -542.01 | -784.22 | -623.04 | -549.58 | -547.5 |
Sale of Property, Plant & Equipment | 0.65 | 0.62 | 1.27 | 0.69 | 22.26 | 6.54 |
Cash Acquisitions | - | - | -674.26 | - | - | - |
Investment in Securities | -300 | -300 | -0.24 | -260 | -2 | -240 |
Other Investing Activities | 0.47 | 60.47 | 510.72 | 0.59 | 0.86 | 1.69 |
Investing Cash Flow | -843.1 | -780.93 | -946.73 | -881.75 | -528.46 | -779.26 |
Short-Term Debt Issued | - | 1,380 | 190 | 410 | 623.2 | 824.12 |
Long-Term Debt Issued | - | 8,778 | 10,226 | 9,995 | 10,270 | 10,251 |
Total Debt Issued | 12,615 | 10,158 | 10,416 | 10,405 | 10,893 | 11,075 |
Short-Term Debt Repaid | - | -1,160 | -404.1 | -841.27 | -1,178 | -440 |
Long-Term Debt Repaid | - | -9,408 | -9,947 | -9,904 | -13,493 | -9,754 |
Total Debt Repaid | -13,264 | -10,568 | -10,351 | -10,746 | -14,671 | -10,194 |
Net Debt Issued (Repaid) | -649.16 | -410.59 | 65.15 | -340.33 | -3,778 | 881.37 |
Issuance of Common Stock | 5 | 5 | 3 | 10 | 5.94 | - |
Common Dividends Paid | -414.37 | -412.84 | -469.07 | -498.58 | -741.6 | -746.79 |
Other Financing Activities | 323.32 | 433.17 | 863.66 | 124.77 | 35.05 | 180 |
Financing Cash Flow | -735.22 | -385.26 | 462.74 | -704.14 | -4,479 | 314.58 |
Foreign Exchange Rate Adjustments | -7.96 | 0.48 | 11.83 | 12.07 | 8.44 | -3.13 |
Net Cash Flow | -414.39 | 10.82 | 757.4 | -549.56 | -3,994 | 582.42 |
Free Cash Flow | 627.68 | 634.53 | 445.35 | 401.23 | 454.81 | 502.75 |
Free Cash Flow Growth | 452.18% | 42.48% | 11.00% | -11.78% | -9.54% | - |
Free Cash Flow Margin | 7.12% | 6.87% | 4.51% | 3.96% | 4.33% | 4.84% |
Free Cash Flow Per Share | 0.37 | 0.37 | 0.26 | 0.25 | 0.27 | 0.29 |
Cash Income Tax Paid | 388.92 | 344.58 | 389.03 | 506.93 | 416.57 | 470.37 |
Levered Free Cash Flow | 159.59 | 543.9 | 379.66 | 156.09 | 181.33 | -902.49 |
Unlevered Free Cash Flow | 371.55 | 769.87 | 666.35 | 469.77 | 555.95 | -500.81 |
Change in Working Capital | -367.66 | -367.66 | -312.09 | -383.39 | -500.29 | -302.32 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.